ArticleChembiochem : a European journal of chemical biology2026
Uracil-Peptide-Pyrene Conjugates as Cu
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We report a series of uracil-triazole-pyrene peptidomimetics (2-4) designed to achieve modular geometric control through peptide linkers of varying length and flexibility. All three compounds exhibited submicromolar affinity for ds-DNA, while compound 4 also showed strong binding to ds-RNA, demonstrating the advantage of combining a uracil recognition unit with an extended pyrene aromatic surface compared to the Pyr-Trp reference ligand and the phenanthridine analog 4'. Structural variations strongly affected Cu(II) coordination. Although Pyr-Trp bound Cu(II) approximately 1000-fold more strongly than the short, rigid compound 2, elongation and increased linker flexibility restored high affinity in 4. Notably, replacing phenanthridine (4') with pyrene (4) enhanced Cu(II) binding by nearly 100-fold, highlighting the superior coordination properties of the pyrene scaffold. Cu(II) complexation significantly enhanced nucleic acid binding exclusively for compound 2, increasing its DNA/RNA affinity 15-fold. The resulting 2-Cu(II) complex displayed exceptional selectivity for poly rA-poly rU, exceeding that of the Pyr-Trp-Cu(II) analog by more than 10-fold, consistent with uracil-mediated Hoogsteen-type recognition. Membrane interactions with POPC MLVs were linker-dependent, producing fluorescence enhancements of up to 1400% (2), 650% (3), and 100% (4). Together with negligible cytotoxicity, these findings indicate that compounds 2-4 represent promising multifunctional platforms for Cu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.